Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events (irrespective of attribution to treatment)
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
1 finding from 1 review
Tranquilisation or asleep not asleep at 2 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep not asleep at 2 hours compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Global outcome ‐ need for benzodiazepine during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcomes: need for benzodiazepine 2 compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: general ‐ no improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: general ‐ no overall improvement compared with COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effect: any serious, specific ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes ‐ not measured · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquilisation or asleep ‐ not asleep by 3 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep ‐ not asleep by 3 hours compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: no overall improvement ‐ at 30 minutes · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: no overall improvement ‐ at 30 minutes compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
1 finding from 1 review
Adverse effects: specific ‐ dystonia · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia (only reported if occurred in… compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ hypertonia/rigidity (only reported if occurred in ≥9%) during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ hypertonia/rigidity (only reported if… compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
1 finding from 1 review
Adverse effects: any serious, specific ‐ dystonia during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: any serious, specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for tranquillisation compared with COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review